Article thumbnail
Location of Repository

The secretion inhibitor Exo2 perturbs trafficking of Shiga toxin between endosomes and the trans-Golgi network

By Robert A. Spooner, Peter Watson, Daniel C. Smith, Frédéric Boal, Mohammed Amessou, Ludger Johannes, Guy J. Clarkson, J. Michael Lord, David J. Stephens and Lynne M. Roberts


The small-molecule inhibitor Exo2 {4-hydroxy-3-methoxy-(5,6,7,8-tetrahydrol[1]benzothieno[2,3-d]pyrimidin-4-yl)hydraz-one benzaldehyde} has been reported to disrupt the Golgi apparatus completely and to stimulate Golgi–ER (endoplasmic reticulum) fusion in mammalian cells, akin to the well-characterized fungal toxin BFA (brefeldin A). It has also been reported that Exo2 does not affect the integrity of the TGN (trans-Golgi network), or the direct retrograde trafficking of the glycolipid-binding cholera toxin from the TGN to the ER lumen. We have examined the effects of BFA and Exo2, and found that both compounds are indistinguishable in their inhibition of anterograde transport and that both reagents significantly disrupt the morphology of the TGN in HeLa and in BS-C-1 cells. However, Exo2, unlike BFA, does not induce tubulation and merging of the TGN and endosomal compartments. Furthermore, and in contrast with its effects on cholera toxin, Exo2 significantly perturbs the delivery of Shiga toxin to the ER. Together, these results suggest that the likely target(s) of Exo2 operate at the level of the TGN, the Golgi and a subset of early endosomes, and thus Exo2 provides a more selective tool than BFA for examining membrane trafficking in mammalian cells

Topics: Research Article
Publisher: Portland Press Ltd.
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2004). 23 genes, 23years later.
  2. (1996). A comparison of the properties of some
  3. (1985). A single amino acid substitution in a hydrophobic domain causes temperature-sensitive cell-surface transport of a mutant viral glycoprotein.
  4. aminothiophene-derived disperse dyes.
  5. (2005). Arf, Sec7 and Brefeldin A: a model towards the therapeutic inhibition of guanine nucleotide-exchange factors.
  6. (2005). BIG1 and BIG2, brefeldin A-inhibited guanine nucleotide-exchange factors for ADP-ribosylation factors. Methods Enzymol.
  7. (2000). Binding site of brefeldin A at the interface between the small G protein ADP-ribosylation factor 1 (ARF1) and the nucleotide-exchange factor Sec7 domain.
  8. (1999). Brefeldin A acts to stabilize an abortive ARF-GDP-Sec7 domain protein complex: involvement of specific residues of the Sec7 domain.
  9. (1991). Brefeldin A causes a microtubule-mediated fusion of the trans-Golgi network and early endosomes.
  10. (1991). Brefeldin A, a drug that blocks secretion, prevents the assembly of non-clathrin-coated buds on Golgi cisternae.
  11. (1991). Brefeldin A’s effects on endosomes, lysosomes, and the TGN suggest a general mechanism for regulating organelle structure and membrane traffic.
  12. (1972). Conditions of access to as-triazino(4,5-a)indole.
  13. (2003). Crystal structure of ARF1*Sec7 complexed with Brefeldin A and its implications for the guanine nucleotide exchange mechanism.
  14. (2003). De novo formation, fusion and fission of COPII coated ER exit sites in mammalian cells.
  15. (1990). Dissociation of a 110-kD peripheral membrane protein from the Golgi apparatus is an early event in brefeldin A action.
  16. (1997). Dissociation of coatomer from membranes is required for brefeldin A-induced transfer of Golgi enzymes to the endoplasmic reticulum.
  17. (1997). Distinct compartmentalization of TGN46 and β1,4-galactosyltransferase in HeLa cells.
  18. (2008). doi:10.1042/BJ20080149 c The Authors Journal compilation c
  19. (2006). Dual specificity of the interfacial inhibitor brefeldin a for arf proteins and sec7 domains.
  20. (1991). Endocytosis and intracellular transport of the glycolipid-binding ligand Shiga toxin in polarized MDCK cells.
  21. (1997). ER-to-Golgi transport visualized in living cells.
  22. (1999). Evidence for a COP-I-independent transport route from the Golgi complex to the endoplasmic reticulum.
  23. (1998). Existence of distinct tyrosylprotein sulfotransferase genes: molecular characterization of tyrosylprotein sulfotransferase-2.
  24. (2003). Exo1: a new chemical inhibitor of the exocytic pathway.
  25. fluorocytosine/cytosine deaminase gene therapies.
  26. (1995). Furin-induced cleavage and activation of Shiga toxin.
  27. (2003). Gangliosides that associate with lipid rafts mediate transport of cholera and related toxins from the plasma membrane to endoplasmic reticulm.
  28. (1992). Inhibition by brefeldin A of a Golgi membrane enzyme that catalyses exchange of guanine nucleotide bound to ARF.
  29. (1985). Microtubules and the organization of the Golgi complex.
  30. (1997). Partitioning of the Golgi apparatus during mitosis in living HeLa cells.
  31. (1992). Perturbation of the morphology of the trans-Golgi network following Brefeldin A treatment: redistribution of a TGN-specific integral membrane protein,
  32. (1996). Primate homologues of rat TGN38: primary structure, expression and functional implications.
  33. (2004). Protein disulphide-isomerase reduces ricin to its A and B chains in the endoplasmic reticulum.
  34. (1997). Proteolytic processing of sulfated secretogranin II in the trans-Golgi network of GH3B6 prolactin cells.
  35. (1999). Rab6 coordinates a novel Golgi to ER retrograde transport pathway in live cells.
  36. (2001). Rapid cycling of lipid raft markers between the cell surface and Golgi complex.
  37. (1989). Rapid redistribution of Golgi proteins into the ER in cells treated with brefeldin A: evidence for membrane cycling from Golgi to ER.
  38. (1994). Retrograde transport from the Golgi complex to the ER of both Shiga toxin and the nontoxic Shiga B-fragment is regulated by butyric acid and cAMP.
  39. (2004). Retrograde transport of cholera toxin from the plasma membrane to the endoplasmic reticulum requires the trans-Golgi network but not the Golgi apparatus in Exo2-treated cells.
  40. (1997). Retrograde transport of KDEL-bearing B-fragment of Shiga toxin.
  41. (2006). Sec16 defines endoplasmic reticulum exit sites and is required for secretory cargo export in mammalian cells.
  42. (1988). Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins.
  43. (2002). Sulfation in the Golgi lumen of Madin-Darby canine kidney cells is inhibited by brefeldin A and depends on a factor present in the cytoplasm and on Golgi membranes.
  44. (1998). Synergistic anticancer effects of ganciclovir/thymidine kinase and
  45. (2001). Targeting of Shiga toxin B-subunit to retrograde transport route in association with detergent-resistant membranes.
  46. (1993). TGN38/41 recycles between the cell surface and the TGN: brefeldin A affects its rate of return to the TGN.
  47. (2006). The association of Shiga-like toxin with detergentresistant membranes is modulated by glucosylceramide and is an essential requirement in the endoplasmic reticulum for a cytotoxic effect.
  48. (2005). The glycosphingolipid globotriaosylceramide in the metastatic transformation of colon cancer.
  49. (2004). The mechanisms of vesicle budding and fusion.
  50. (1979). Thieno[2,3-d]pyrimidines as potential chemotherapeutic agents.
  51. (1988). Tyrosine sulfation and the secretory pathway.
  52. (1987). Tyrosine sulfation is a trans-Golgi-specific protein modification.
  53. (1983). Tyrosine-O-sulfated proteins of PC12 pheochromocytoma cells and their sulfation by a tyrosylprotein sulfotransferase.
  54. (1998). Tyrosylprotein sulfotransferase: purification and molecular cloning of an enzyme that catalyzes tyrosine O-sulfation, a common posttranslational modification of eukaryotic proteins.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.